Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
FAQ
- What is Arcus Biosciences's D&A?
- Arcus Biosciences (RCUS) reported D&A of $3M in Q2 2026.
- How has Arcus Biosciences's D&A changed year-over-year?
- Arcus Biosciences's D&A increased by 50.0% year-over-year, from $2M to $3M.
- What is the long-term trend for Arcus Biosciences's D&A?
- Over 4 years (2021 to 2025), Arcus Biosciences's D&A has grown at a 25.7% compound annual growth rate (CAGR), from $4M to $10M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Arcus Biosciences's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude